Yulong Jin*, Li Xu*, Xiaodong Wu†, Juan Feng*, Mimi Shu*, Hongtao Gu*, Guangxun Gao*,
Jinyi Zhang‡, Baoxia Dong*, Xiequn Chen*
Oncology Research, Vol.27, No.6, pp. 729-737, 2019, DOI:10.3727/096504018X15443011011637
Abstract Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibodysecreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant
antimyeloma activity and prolongs the median survival of MM patients. However, MM remains incurable
predominantly due to acquired drug resistance and disease relapse. -Catenin, a key effector protein in
the canonical Wnt signaling pathway, has been implicated in regulating myeloma cell sensitivity to BZM.
Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based
on its gene-specific DNA hypomethylation. DAC has been implicated in modulating Wnt/… More >
Login
Register
